510(k) Report

510(k) · Cleared

Cleared

Xenta Drug Screen Cup, Xenta Drug Screen Dipcard

K222955510(k) TraditionalCleared Feb 6, 2023132-day reviewClass II21 CFR 862.3650

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Xenta Biomedical Science Co., Ltd. · DJG Enzyme Immunoassay, Opiates

Cleared on Feb 6, 2023 as substantially equivalent to K153050 (Co-Innovation Biotech Co., Ltd., 2016) after a 132-day review. Its family tree reaches back 8 generations to 1995.

Decided
Feb 6, 2023
Review
132 days
Class
Class II
Product code
DJG
Recalls
None
Predicates
1

Its longest line of descent runs back 8 generations to K945610 (1995). 30 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 8 generations backK945610 Abusign (TM) Amp, Doa-Amp, Accusign (TM) Amp-Doa-Amp, Biosign (TM)…Princeton BioMeditech Corp. · 1995
  2. 7 generations backK011673 Acon Amp One Step Amphetamine Test Strip, Acon Amp One Step…ACON Laboratories, Inc. · 2001
  3. 6 generations backK020313 Acon One Step Multi-Drug Multi-Line Screen Test Card; Acon One Step…Acon Laboratories Co. · 2002
  4. 5 generations backK031759 Acon Spectrum Multi-Drug Multi-Line Drug Screen Test Card and Acon…ACON Laboratories, Inc. · 2003 · Recalled
  5. 4 generations backK061718 Innovacon Spectrum II Test CardInnovacon, Inc. · 2006 · Recalled
  6. 3 generations backK122809 Advin Multi-Drug Screen Test Cassette, Dip Card and CupAdvin Biotech · 2013
  7. 2 generations backK140748 One Step Single/Multi-Drug Test Cup, One Step Single/Multi-Drug Test…Co-Innovation Biotech Co., Ltd. · 2014
  8. 1 generation backK153050 Rapid Single/Multi-drug Test Cup, Rapid Single/Multi-drug Test DipcardCo-Innovation Biotech Co., Ltd. · 2016
  9. This deviceK222955 Xenta Drug Screen Cup, Xenta Drug Screen DipcardXenta Biomedical Science Co., Ltd. · 2023
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−8K945610Abusign (TM) Amp, Doa-Amp, Accusign (TM) Amp-Doa-Amp, Biosign (TM) Amp, Doa-AmpPrinceton BioMeditech Corp.1995—
−7K011673Acon Amp One Step Amphetamine Test Strip, Acon Amp One Step Amphetamine Test…ACON Laboratories, Inc.2001—
−6K020313Acon One Step Multi-Drug Multi-Line Screen Test Card; Acon One Step Multi-Drug…Acon Laboratories Co.2002—
−5K031759Acon Spectrum Multi-Drug Multi-Line Drug Screen Test Card and Acon Spectrum…ACON Laboratories, Inc.20031
−4K061718Innovacon Spectrum II Test CardInnovacon, Inc.20066
−3K122809Advin Multi-Drug Screen Test Cassette, Dip Card and CupAdvin Biotech2013—
−2K140748One Step Single/Multi-Drug Test Cup, One Step Single/Multi-Drug Test DipcardCo-Innovation Biotech Co., Ltd.2014—
−1K153050Rapid Single/Multi-drug Test Cup, Rapid Single/Multi-drug Test DipcardCo-Innovation Biotech Co., Ltd.2016—
0 (this device)K222955Xenta Drug Screen Cup, Xenta Drug Screen DipcardXenta Biomedical Science Co., Ltd.2023—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199620
199810
199910
200010
200170
200220
200320
200430
200510
200610
201410
FIG. 1 — Lineage of K222955, 1995–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DJG? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DJG device

  1. #1 K232659 Dochek® Multi-Drug Urine Test Cup Rx, Dochek®…score 17.6 · 8 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K153050Rapid Single/Multi-drug Test Cup, Rapid Single/Multi-drug Test Dipcard
Summary page 4
…21 CFR 862.3610 Methamphetamine test system Device class: ClassⅡ Panel: Toxicology Product code: DIO,DJG,LDJ,DJC 4. The Predicate Devices K153050 Rapid Single/Multi-drug Test Cup Rapid Single/Multi-drug Test Dipcard 5. Device Description…
Co-Innovation Biotech Co., Ltd.2016—

Also cleared against K153050: 4 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 28 years and passes through 7 companies; a new generation was cleared every 3.3 years on median.
  • 2 of the 30 ancestors have a recall of any class.
  • 4 other devices also cite its predicate K153050.

How does its category compare?

All DJG devices

DJG Enzyme Immunoassay, Opiates: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · DJG

3in 2025

2007: 22008: 22009: 22010: 62011: 62012: 52013: 52014: 92015: 122016: 22017: 42018: 52019: 32020: 52021: 32022: 22023: 102024: 52025: 32026 (partial year): 3
2007high 12 (2015) · low 2 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DJG

31in 2025

2010: 187 days median2011: 233 days median2012: 95 days median2013: 60 days median2014: 62 days median2015: 141 days median2017: 101 days median2018: 134 days median2019: 235 days median2020: 30 days median2021: 422 days median2023: 140 days median2024: 150 days median2025: 31 days median2026 (partial year): 157 days median
2007high 422 (2021) · low 30 (2020)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · DJG

2in 2025

2011: 12019: 12025: 2
2007high 2 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DJG

1in 2025

2011: 42012: 12013: 42015: 32016: 22017: 12018: 12021: 22022: 12024: 32025: 1
2007high 4 (2011) · low 0 (2007)2025

MAUDE reports naming product code DJG, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20082—00
20092—00
2010618700
2011623314
201259501
201356004
201496200
20151214103
20162—02
2017410101
2018513401
2019323510
202053000
2021342202
20222—01
20231014000
2024515003
202533121
202631570—

What is it indicated for?

Xenta Drug Screen Cup and Xenta Drug Screen Dipcard are lateral flow chromatographic immunoassays designed to qualitatively detect the presence of drugs and drug metabolites in human urine at the following cut-off concentrations: Test Calibrator Cut-off level Marijuana (THC) Delta-9-THC-COOH 50 ng/mL Cocaine (COC) Benzoylecgonine 300 ng/mL Methylenedioxymethamphetamine (MDMA) 3,4-Methylenedioxymethamphetamine 500 ng/mL Methamphetamine (MET)…

Read the full statement (155 words)

Xenta Drug Screen Cup and Xenta Drug Screen Dipcard are lateral flow chromatographic immunoassays designed to

qualitatively detect the presence of drugs and drug metabolites in human urine at the following cut-off concentrations:

Test Calibrator Cut-off level

Marijuana (THC) Delta-9-THC-COOH 50 ng/mL

Cocaine (COC) Benzoylecgonine 300 ng/mL

Methylenedioxymethamphetamine (MDMA) 3,4-Methylenedioxymethamphetamine 500 ng/mL

Methamphetamine (MET) D-Methamphetamine 1000 ng/mL

Morphine 300 (MOP) Morphine 300 ng/mL

The tests contain two formats: 1) Test Cup and 2) Test Dipcard. The tests may be configured as single drug tests or

multiple drug tests in any combination of the drug analytes listed in the table above. These tests are intended for in vitro

diagnostics use. They are intended for prescription use.

The assays provide only a preliminary analytical test result. Gas Chromatography/Mass spectrometry (GC/MS) is the

preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse

test result, particularly when preliminary positive results are indicated.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K222955: Xenta Drug Screen Cup, Xenta Drug Screen Dipcard.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K222955

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026